Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Mar 31;6(3):e009669.
doi: 10.1136/bmjopen-2015-009669.

Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study

Oriana Ciani  1 , Erik Arendsen  2 , Martin Romancik  3 , Richard Lunik  4 , Elisabetta Costantini  5 , Manuel Di Biase  5 , Giuseppe Morgia  6 , Eugenia Fragalà  6 , Tomaskin Roman  7 , Marian Bernat  8 , Giorgio Guazzoni  9 , Rosanna Tarricone  10 , Massimo Lazzeri  9
Affiliations
Observational Study

Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study

Oriana Ciani et al. BMJ Open. .

Abstract

Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and chondroitin sulfate (HA+CS) versus current standard management in adult women with recurrent urinary tract infections (RUTIs).

Setting: A European Union-based multicentre, retrospective nested case-control study.

Participants: 276 adult women treated for RUTIs starting from 2009 to 2013.

Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/immunoactive prophylaxis/probiotics/cranberry).

Primary and secondary outcome measures: The primary outcome was occurrence of bacteriologically confirmed recurrence within 12 months. Secondary outcomes were time to recurrence, total number of recurrences, health-related quality of life and healthcare resource consumption. Crude and adjusted results for unbalanced characteristics are presented.

Results: 181 patients treated with HA+CS and 95 patients treated with standard of care from 7 centres were included. The crude and adjusted ORs (95% CI) for the primary end point were 0.77 (0.46 to 1.28) and 0.51 (0.27 to 0.96), respectively. However, no evidence of improvement in terms of total number of recurrences (incidence rate ratio (95% CI), 0.99 (0.69 to 1.43)) or time to first recurrence was seen (HR (95% CI), 0.99 (0.61 to 1.61)). The benefit of intravesical HA+CS therapy improves when the number of instillations is ≥ 5.

Conclusions: Our results show that bladder instillations of combined HA+CS reduce the risk of bacteriologically confirmed recurrences compared with the current standard management of RUTIs. Total incidence rates and hazard rates were instead non-significantly different between the 2 groups after adjusting for unbalanced factors. In contrast to what happens with antibiotic prophylaxis, the effectiveness of the HA+CS reinstatement therapy improves over time.

Trial registration number: NCT02016118.

Keywords: Antimicrobial Resistance; Hyaluronic acid; chondroitin sulphate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram describing numbers of individuals at each stage of study. HA+CS, hyaluronic acid and chondroitin sulfate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Laupland KB, Ross T, Pitout JD et al. . Community-onset urinary tract infections: a population-based assessment. Infection 2007;35:150–3. 10.1007/s15010-007-6180-2 - DOI - PubMed
    1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(Suppl 1A):5S–13S. 10.1016/S0002-9343(02)01054-9 - DOI - PubMed
    1. Foxman B, Barlow R, D'Arcy H et al. . Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000;10:509–15. 10.1016/S1047-2797(00)00072-7 - DOI - PubMed
    1. Hooton TM, Scholes D, Hughes JP et al. . A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996;335:468–74. 10.1056/NEJM199608153350703 - DOI - PubMed
    1. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:653–60. 10.1038/nrurol.2010.190 - DOI - PubMed

Publication types

Associated data